Citi analyst Patrick Donnelly downgraded Illumina (ILMN) to Neutral from Buy with a price target of $165, down from $190. The firm sees less clarity on the conpany’s growth ramp given more pronounced pricing headwinds in the first half of 2025 from the NovaSeq X ramp and believes the cost out story is appropriately priced into the multiple.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina enters licensing agreement with Lonza
- Illumina releasing expanded version of TruSight Oncology portfolio
- Cantor sees six changes to Nasdaq 100 Index in December rebalance
- Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
- Illumina resumed with an Equal Weight at Morgan Stanley